Stephen George Dilly, President and CEO at Aimmune Therapeutics, Inc. (AIMT), sold 179,373 shares at $31.20 ($5.5M) on 2018-06-06, disclosed to the SEC on 2018-06-08.
Open-market sale of $5.5M AIMT by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.20 | 30,465 | $951K | 17.2% |
| 2 | $30.95 | 32,098 | $993K | 17.9% |
| 3 | $30.95 | 32,098 | $993K | 17.9% |
| 4 | $31.58 | 500 | $16K | 0.3% |
| 5 | $30.70 | 42,106 | $1.3M | 23.3% |
| 6 | $30.70 | 42,106 |
| $1.3M |
| 23.3% |
| Total | $30.88 avg | 179,373 | $5.5M | 100% |
| Filing → |
| SRRA | BUY | 2021-05-20 | $178K | — | Filing → |
| SGMO | SELL | 2020-03-20 | $210K | — | Filing → |
| SGMO | SELL | 2020-03-18 | $90K | — | Filing → |